Could investing in the pharmaceutical giant pay off over the next five years? I think so, and here is why. AbbVie has a ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s Drug Agency (CDA-AMC) has recommended SKYRIZI ® ...

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease affecting the large intestine, causing persistent inflammation and ulceration of the colon’s lining. Common symptoms include ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Oct 31 (Reuters) - AbbVie (ABBV.N), opens new tab said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, which in 2024 yielded discounts ...

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and ...